Form 4 for GILD Gilead Sciences
Accepted 2026-03-12 00:00:00 ET · period of report 2026-03-10 · accession 0001310204-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-12 | 2026-03-10 | GILD | Dickinson Andrew D | CFO | M - OptEx | — | +6,469 | 185.3K | +4% | — |
| D | 2026-03-12 | 2026-03-10 | GILD | Dickinson Andrew D | CFO | F - Tax | $148.56 | -3,147 | 182.2K | -2% | -$467.5K |
| D | 2026-03-12 | 2026-03-10 | GILD | Dickinson Andrew D | CFO | M - OptEx | — | -6,469 | 21.1K | -24% | — |
| DM | 2026-03-12 | 2026-03-10 | GILD | Dickinson Andrew D | CFO | A - Grant | $0.00 | +45.5K | 35.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-10 | M | A | 6,469 | — | 185,338 | D | — | — | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. |
| 2 | Common | Common Stock | 2026-03-10 | F | D | 3,147 | $148.56 | 182,191 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2026-03-10 | M | D | 6,469 | — | 21,057 | D | — · — to — | 6,469 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 4 | Derivative | Restricted Stock Unit | 2026-03-10 | A | A | 9,590 | — | 30,647 | D | — · — to — | 9,590 Common Stock | (F1) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. (F2) The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |
| 5 | Derivative | Non-qualified Stock Option (Right to Buy) | 2026-03-10 | A | A | 35,880 | $0.00 | 35,880 | D | $148.56 · — to 2036-03-10 | 35,880 Common Stock | (F3) The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. |